Every FDA-approved drug, including peptide drugs like semaglutide, tirzepatide, or tesamorelin, comes with a document called the package insert, more formally known as the prescribing information or label. It's dense, technical, and rarely read cover to cover by patients, but it's also the single most complete, regulator-reviewed source of information about what a drug actually does and doesn't do. Knowing how it's organized makes it far more useful.
Boxed Warning
If a drug carries the FDA's most serious safety warning, it appears at the very top of the label in a bordered box, commonly called a "black box warning." This site has a separate guide dedicated to what a boxed warning means and which peptides carry one; its presence flags a specific, serious risk the FDA has determined needs the most prominent possible placement, not a general statement that the drug is unusually dangerous.
Indications and Usage
This section states exactly what condition or conditions the drug is approved to treat, and in which patient populations. This is the most important section for understanding a drug's actual approved use, since it's common for a drug to be widely discussed for uses well beyond what's listed here.
Dosage and Administration
This section lays out the FDA-reviewed dosing regimen used in the drug's clinical trials, including starting doses, titration schedules, and administration method. It reflects the specific regimen that was actually studied and found to have an acceptable risk-benefit profile, which is why deviating from it removes the basis for the drug's demonstrated safety and efficacy data.
Contraindications
This is a specific, usually short list of situations in which the drug should not be used at all, such as a personal or family history of certain thyroid cancers for some GLP-1 drugs. Contraindications are treated differently from warnings: they represent conditions under which the risk is considered to outweigh any potential benefit categorically, not just a risk to be weighed and monitored.
Warnings and Precautions
This longer section covers risks that don't rise to a contraindication but still require caution, monitoring, or patient counseling, such as risk of pancreatitis or gallbladder problems associated with some GLP-1 drugs. This section is often the most clinically useful part of the label for understanding a drug's real-world risk profile in day-to-day use.
Adverse Reactions
This section reports the specific side effects observed in the drug's clinical trials, generally including how frequently each occurred compared to placebo. Because this data comes directly from controlled trials, it gives a more precise picture of a drug's actual side-effect frequency than anecdotal reports, though real-world experience can still surface additional patterns not captured in the original trial population.
Drug Interactions
This section lists other medications that can affect, or be affected by, the drug in question, along with guidance on managing those interactions, such as adjusted insulin dosing when starting a GLP-1 drug in a patient already on insulin.
Use in Specific Populations
This covers what's known, or explicitly not known, about the drug's use in groups such as pregnant or breastfeeding patients, pediatric patients, and older adults. Gaps here reflect gaps in the actual clinical trial data for that population, not necessarily evidence that the drug is unsafe for that group.
Clinical Studies
This section summarizes the actual trials that supported approval, including trial design and key efficacy results. It's the most direct link between a drug's label and the primary research this site regularly discusses in its coverage of specific clinical trial programs.
Patient Counseling Information
Usually near the end, this section is written to guide what a prescriber should discuss directly with a patient, covering practical points like injection technique, warning signs to report, and storage instructions.
The Bottom Line
A package insert is not designed for easy reading, but it's a standardized, FDA-reviewed document, which makes it a far more reliable starting point than marketing material or anecdotal claims when trying to understand exactly what an approved drug does, who it's approved for, and what risks it carries. Patients with questions about their own prescribing information should bring it directly to their doctor or pharmacist rather than trying to interpret unclear sections alone.